Key points are not available for this paper at this time.
Objective: To evaluate Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions’ impact on the diagnostic test accuracy (DTA) of MRI for prostate cancer (PC) and to derive the prevalence of PC within each PI-RADS category. Methods: MEDLINE and Embase were searched until April 10, 2020 for studies reporting on the DTA of MRI by PI-RADS category. Accuracy metrics were calculated using a bivariate random-effects meta-analysis with PI-RADS three lesions treated as a positive test, negative test, and excluded from the analysis. Differences in DTA were assessed utilizing meta-regression. PC prevalence within each PI-RADS category was estimated with a proportional meta-analysis. Results: In total, 26 studies reporting on 12,913 patients (4,853 with PC) were included. Sensitivities for PC in the positive, negative, and excluded test groups were 96% (95% confidence interval CI 92–98), 82% (CI 75-87), and 95% (CI 91-97), respectively. Specificities for the positive, negative, and excluded test groups were 33% (CI 23-44), 71% (CI 62-79), and 52% (CI 37-66), respectively. Meta-regression demonstrated higher sensitivity (p 0.001) and lower specificity (p 0.001) in the positive test group compared to the negative group. Clinically significant PC prevalences were 5.9% (CI 0-17.1), 11.4% (CI 6.5–17.3), 24.9% (CI 18.4–32.0), 55.7% (CI 47.8–63.5), and 81.4% (CI 75.9–86.4) for PI-RADS categories 1, 2, 3, 4 and 5, respectively. Conclusion: PI-RADS category 3 lesions can significantly impact the DTA of MRI for PC detection. A low prevalence of clinically significant PC is noted in PI-RADS category 1 and 2 cases. Advances in knowledge: Inclusion or exclusion of PI-RADS category 3 lesions impacts the DTA of MRI for PC detection.
Wadera et al. (Thu,) studied this question.